陈颖王瑾△ 刘元昉张佼佼陈丽.利妥昔单抗联合CHOP化疗治疗感染乙肝病毒的
非霍奇金淋巴瘤患者的安全性分析[J].现代生物医学进展英文版,2014,14(10):1871-1874. |
利妥昔单抗联合CHOP化疗治疗感染乙肝病毒的
非霍奇金淋巴瘤患者的安全性分析 |
Safety Analysis of Rituximab Combined with Chemotherapyin the Treatment of B ceH non-Hodgkin S lymphoma PatientsPlicated with HBV Infection |
|
DOI: |
中文关键词: 利妥昔单抗 乙肝病毒 非霍奇金淋巴瘤 化疗 |
英文关键词: Rituximab Hepatitis B virus Non-Hodgkin S lymphoma Chemotherapy |
基金项目: |
|
Hits: 729 |
Download times: 795 |
中文摘要: |
摘要目的:观察利妥昔单抗与CHOP 化疗联合治疗感染乙肝病毒(HBV)的非霍奇金淋巴瘤(NHL)患者的有效性及安全性。方
法:选取2010 年6 月至2013 年6 月35 例B 细胞NHL住院患者,分为两组,观察组(n=13)为感染HBV 患者,接受利妥昔单抗
-CHOP 化疗方案;对照组(n=22)为非感染HBV 的患者,单纯接受CHOP 化疗方案,两组治疗4~6 疗程,观察两组患者治疗的疗
效及肝功能。结果:观察组完全缓解率(CR率)为76.92% ,对照组CR率为40.91%(P<0.05),两组差异有统计学意义。观察组肝
功能损害I~Ⅱ级发生率为23.07%,对照组肝功能损害I~Ⅱ级发生率18.18%(P>0.05),观察组毒副反应发生率为30.77%,对照
组毒副反应发生率为22.72%(P>0.05),两组在肝功能损害及毒副反应上差异无统计学意义。两组患者HBV 均未再激活。结论:感
染HBV的B 细胞NHL患者用R-CHOP 联合化疗方案治疗,以及在化疗时预防性、足疗程的抗病毒治疗,可以减少HBV再激活
的发生,并且可以降低肝功损害率。 |
英文摘要: |
ABSTRACT Objective:To observe the effectiveness and safety of the treatment about rituximab combined with CHOP chemotherapy
on the non-hodgkin's lymphoma(NHL)patients with HBV infection. Methods:35 B-cell NHL patients(from 2010 to 2013)were
divided into two groups: observation group (patients with HBV infection, n=13), They were all treated four to six periods of treatment
with R-CHOP regimen, and matched group (patients without HBV infection, n=22), They were all treated four to six periods of treatment
with CHOP regimen. Then, the treatment about the effect and liver function were observed. Results:The complete response rate Was
76.92%in the observation group,while 40.91% in the matched group (P<0.05). There was statistically significant difference in both
groups. The rate of I-II class hepatic damage Was 23.07%in the observation group, and 18.18%in the matched group (P>0.05).The
incidence of adverse reaction was 30.77%in the observation group and 22.72%in the matched group (P>0.05). There was no statistically
significant difference about hepatic damage or incidence of adverse reaction in both groups.Conclusion: It can reduce the incidence of
HBV reactivation and the rate of hepatic damage, While HBV infection of B cell NHL patients use the R-CHOP treatment Combined
chemotherapy scheme, and full course of antiviral treatment during the chemotherapy. |
View Full Text
View/Add Comment Download reader |
Close |